Venkata Raghava Mohan on Muck Rack

Venkata Raghava Mohan

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Venkata Raghava

Contact Venkata Raghava, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Author Correction: Impact of the indigenous rotavirus vaccine Rotavac in the Universal Immunization Program in India during 2016–2020 - Nature Medicine

|
By Nayana Nair, Samarasimha N. Reddy, Venkata Raghava Mohan, Gagandeep Kang
| Nature Verified
Correction to: Nature Medicine https://doi.org/10.1038/s41591-025-03998-9, published online 7 October 2025. In the version of the article initially published, Tintu Varghese (The Wellcome Trust Research Laboratory, Christian Medical College, Vellore, India) was missing from the author list and is now included in the HTML and PDF versions of the article.
Open in Who Shared View Duplicates (5) Issue with article?

Impact of the indigenous rotavirus vaccine Rotavac in the Universal Immunization Program in India during 2016–2020 - Nature Medicine

|
By Nayana Nair, Venkata Raghava Mohan, Gagandeep Kang, Samarasimha N. Reddy
| Nature Verified
Abstract In 2016, India introduced Rotavac (G9P[11]), an indigenous oral rotavirus vaccine administered at 6, 10 and 14 weeks of age through the Universal Immunization Program. Evaluating its effectiveness under routine programmatic conditions is critical, given the variable performance of rotavirus vaccines in low- and middle-income countries.
Open in Who Shared Issue with article?

Environmental surveillance for Salmonella Typhi as a tool to estimate the incidence of typhoid fever in low-income populations

|
By Jonathan Rigby, Venkata Raghava Mohan, Christopher B. Uzzell, Catherine M. Troman
| medRxiv
Abstract Background The World Health Organisation recommends prioritised use of recently prequalified typhoid conjugate vaccines in countries with the highest incidence of typhoid fever. However, representative typhoid surveillance data are lacking in many low-income countries because of the costs and challenges of diagnostic clinical microbiology.
Open in Who Shared Issue with article?
See all 4 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified